Pushpakom相关文献与解析，生知库 | 链接生命科学的每一步

Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials

心血管药物与 COVID-19 临床结局：随机对照试验的系统评价和荟萃分析

期刊:British Journal of Clinical Pharmacology

Asiimwe, Innocent G; Pushpakom, Sudeep P; Turner, Richard M; Kolamunnage-Dona, Ruwanthi; Jorgensen, Andrea L; Pirmohamed, Munir

发表日期：2022

文献求助收藏

Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis

心血管药物与 COVID-19 临床结局：一项动态系统评价和荟萃分析

期刊:British Journal of Clinical Pharmacology

影响因子:3

doi:10.1111/bcp.14927

Asiimwe, Innocent G; Pushpakom, Sudeep; Turner, Richard M; Kolamunnage-Dona, Ruwanthi; Jorgensen, Andrea L; Pirmohamed, Munir

发表日期：2021

文献求助收藏

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy

TAILoR（替米沙坦治疗人类免疫缺陷病毒[HIV]感染者的胰岛素抵抗）：一项采用适应性设计、剂量范围递增的IIb期随机试验，旨在评估替米沙坦降低接受联合抗逆转录病毒疗法的HIV感染者胰岛素抵抗的疗效

期刊:Clinical Infectious Diseases

影响因子:7.3

doi:10.1093/cid/ciz589

Pushpakom, Sudeep; Kolamunnage-Dona, Ruwanthi; Taylor, Claire; Foster, Terry; Spowart, Cath; García-Fiñana, Marta; Kemp, Graham J; Jaki, Thomas; Khoo, Saye; Williamson, Paula; Pirmohamed, Munir

Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts

尼洛替尼诱导的代谢功能障碍：一项利用体外脂肪细胞模型和患者队列的转化研究的启示

期刊:Leukemia

影响因子:13.4

doi:10.1038/s41375-018-0337-0

Sadiq, Soban; Owen, Euan; Foster, Terry; Knight, Katy; Wang, Lihui; Pirmohamed, Munir; Clark, Richard E; Pushpakom, Sudeep

Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro

体外实验表明，替米沙坦可逆转抗逆转录病毒药物诱导的脂肪细胞毒性和胰岛素抵抗。

期刊:

影响因子:

doi:10.1177/1479164118757924

Pushpakom, Sudeep P; Adaikalakoteswari, Antonysunil; Owen, Andrew; Back, David J; Tripathi, Gyanendra; Kumar, Sudhesh; McTernan, Philip; Pirmohamed, Munir

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy

替米沙坦与 HIV 感染者胰岛素抵抗 (TAILoR)：一项剂量范围 II 期随机开放标签试验方案，旨在评估替米沙坦作为降低接受联合抗逆转录病毒疗法的 HIV 感染者胰岛素抵抗的策略

期刊:BMJ Open

影响因子:2.3

doi:10.1136/bmjopen-2015-009566

Pushpakom, Sudeep P; Taylor, Claire; Kolamunnage-Dona, Ruwanthi; Spowart, Catherine; Vora, Jiten; García-Fiñana, Marta; Kemp, Graham J; Whitehead, John; Jaki, Thomas; Khoo, Saye; Williamson, Paula; Pirmohamed, Munir

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

在接受胰高血糖素样肽-1 (GLP-1) 受体激动剂治疗的肥胖型 2 型糖尿病患者中，血糖改善与肝脏脂肪减少相关。

期刊:PLoS One

影响因子:2.6

doi:10.1371/journal.pone.0050117

Cuthbertson, Daniel J; Irwin, Andrew; Gardner, Chris J; Daousi, Christina; Purewal, Tej; Furlong, Niall; Goenka, Niru; Thomas, E Louise; Adams, Valerie L; Pushpakom, Sudeep P; Pirmohamed, Munir; Kemp, Graham J

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

德国艾滋病防治能力网络中ABCC10多态性与奈韦拉平血浆浓度的相关性

期刊:Pharmacogenetics and Genomics

影响因子:1.7

doi:10.1097/FPC.0b013e32834dd82e

Liptrott, Neill J; Pushpakom, Sudeep; Wyen, Christoph; Fätkenheuer, Gerd; Hoffmann, Christian; Mauss, Stefan; Knechten, Heribert; Brockmeyer, Norbert H; Hopper-Borge, Elizabeth; Siccardi, Marco; Back, David J; Khoo, Saye H; Pirmohamed, Munir; Owen, Andrew

发表日期：2012

文献求助收藏

Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events

用于硫嘌呤S-甲基转移酶基因单核苷酸多态性分型的微流控平台，以评估药物不良事件风险

期刊:Journal of Molecular Diagnostics

影响因子:3.4

doi:10.2353/jmoldx.2007.070014

Chowdhury, Jeeshan; Kaigala, Govind V; Pushpakom, Sudeep; Lauzon, Jana; Makin, Alistair; Atrazhev, Alexey; Stickel, Alex; Newman, William G; Backhouse, Christopher J; Pilarski, Linda M

发表日期：2007

文献求助收藏

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta-Analysis

UGT1A1 和 Sacituzumab Govitecan 毒性：系统评价和荟萃分析

Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials

心血管药物与 COVID-19 临床结局：随机对照试验的系统评价和荟萃分析

Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis

心血管药物与 COVID-19 临床结局：一项动态系统评价和荟萃分析

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy

TAILoR（替米沙坦治疗人类免疫缺陷病毒[HIV]感染者的胰岛素抵抗）：一项采用适应性设计、剂量范围递增的IIb期随机试验，旨在评估替米沙坦降低接受联合抗逆转录病毒疗法的HIV感染者胰岛素抵抗的疗效

Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts

尼洛替尼诱导的代谢功能障碍：一项利用体外脂肪细胞模型和患者队列的转化研究的启示

Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro

体外实验表明，替米沙坦可逆转抗逆转录病毒药物诱导的脂肪细胞毒性和胰岛素抵抗。

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy

替米沙坦与 HIV 感染者胰岛素抵抗 (TAILoR)：一项剂量范围 II 期随机开放标签试验方案，旨在评估替米沙坦作为降低接受联合抗逆转录病毒疗法的 HIV 感染者胰岛素抵抗的策略

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

在接受胰高血糖素样肽-1 (GLP-1) 受体激动剂治疗的肥胖型 2 型糖尿病患者中，血糖改善与肝脏脂肪减少相关。

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

德国艾滋病防治能力网络中ABCC10多态性与奈韦拉平血浆浓度的相关性

Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events

用于硫嘌呤S-甲基转移酶基因单核苷酸多态性分型的微流控平台，以评估药物不良事件风险